The US group Johnson & Johnson closed last year with an increase in sales and profits thanks to new medicines and a flourishing medical technology business.
For 2026, CEO Joaquin Duato is targeting further increases despite the regulation on drug discounts recently agreed with the US government, as the company announced on Wednesday.
The company wants to increase its revenue to between 100 and 101 billion US dollars this year, after sales rose by 6 percent to 94.2 billion dollars (80.5 billion euros) in 2025. This was slightly less than experts expected. After the news, the share came under some pressure before the trading session, although the sales forecast was again better than expected.
In addition to increasing sales, Johnson & Johnson also wants to further increase its earnings in 2026. Earnings of $11.43 to $11.63 per share are expected on an adjusted basis.
For comparison: in 2025, the group generated $10.79 per share, a good 8 percent more than the year before. Despite the costs for the approximately $3 billion takeover of the biotech company Halda Therapeutics, which was completed in the final quarter, the bottom line was a profit of $26.8 billion, around 90 percent more than in the previous year.
According to the statement, company leader Duato described 2025 as “a catapult year for Johnson & Johnson”. The group is “driven by the strongest portfolio and pipeline in our history.” A new era of accelerated growth has begun for the group, thanks to medical innovations in the six core business areas of oncology, immunology, neuroscience, cardiovascular, surgery and ophthalmology.
In 2025, the company raised its targets several times because of the good run. For example, with high growth in cancer drugs such as Darzalex, Carvykti and Rybrevant, the manufacturer was able to more than make up for the loss in sales of the psoriasis drug Stelara – which suffers from competition from copycats.
In premarket trading on the NYSE, Johnson & Johnson shares were temporarily 2.49 percent lower at $212.80.
/tav/lew/mis
NEW BRUNSWICK (dpa-AFX)
By the way: Johnson Johnson and other US stocks can even be traded on finanzen.net ZERO until 11 p.m. (without order fees, plus spreads). Open a depot now for free and secure a new customer bonus!
Selected leverage products on Johnson Johnson
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Johnson Johnson
The leverage must be between 2 and 20
Advertising